Edesa Biotech, Inc.

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and eventually commercializing therapies for inflammatory and immune-related diseases. Its pipeline is centered on two areas: medical dermatology, including EB06 for vitiligo and EB01 for chronic allergic contact dermatitis, and respiratory disease, including EB05 (paridiprubart) for acute respiratory distress syndrome and related indications.

10.67

10.67

— Edesa Biotech, Inc.
%
Medical Dermatology45% Pipeline assets aimed at autoimmune and inflammatory skin diseases, including vitiligo and allergic contact dermatitis.
Respiratory / Host-Directed Therapeutics45% Clinical programs targeting severe respiratory inflammation and ARDS, led by EB05 (paridiprubart).
Licensing and Partnering10% Out-licensing or collaboration arrangements for assets that are not being commercialized directly.

Edesa does not yet have commercial customers because it is still in clinical development and has not launched approved...

  • No commercial customers yetprimary

    The company is clinical-stage and has no marketed products, so it does not currently sell investigational medicines to end users.

  • Healthcare providers and hospitalsprimary

    If approved, physicians, hospitals, and health systems would prescribe or administer EB06 and EB05 for vitiligo and ARDS patients.

  • Pharmaceutical licensing partnerssecondary

    Potential partners may acquire regional rights or co-develop EB01 and other assets to provide commercialization infrastructure.

  • Government and grant agenciessecondary

    Public-sector programs fund parts of EB05 development and reimburse eligible R&D expenses, supporting the pipeline.

Edesa is headquartered in Ontario, Canada, and operates through subsidiaries in Canada and the United States...

  • •Headquartered in Markham, Ontario, Canada
  • •Operates through subsidiaries in Ontario and California
  • •North America is the core development and launch focus
  • •Health Canada and FDA pathways are both relevant
  • •May use partners for markets outside North America

Edesa’s strategy is to advance a small number of mechanistically differentiated drug candidates through...

01
Advance EB06 into Phase 2 proof-of-conceptshort-term

Vitiligo is a clear clinical target and a successful study would strengthen the dermatology pipeline.

02
Develop and partner EB01short-term

EB01 is Phase 3-ready and partnering can provide capital and commercialization reach without building a full sales force.

03
Expand EB05 clinical and partnering opportunitiesmedium-term

Positive ARDS data can create a path to regulatory discussions, government support, and broader respiratory indications.

04
Secure additional capital and non-dilutive fundingshort-term

The company disclosed going-concern uncertainty and needs funding to continue development.

Edesa faces the classic risks of a clinical-stage biotech: no product revenue, dependence on capital markets, and...

critical

Going-concern and financing risk

The company states existing cash and expected reimbursements may not fund operations for 12 months without additional capital or reduced spending.

Scope
Corporate liquidity and pipeline continuity
Materiality
high
high

Clinical development failure

EB06, EB01, and EB05 are still in development, so negative data would reduce or eliminate future value.

Scope
Pipeline assets
Materiality
high
high

Regulatory approval delays

The company must obtain FDA, Health Canada, or other approvals before commercialization, and timelines are uncertain.

Scope
EB06 and EB05 programs
Materiality
high
high

Third-party manufacturing and clinical operations dependence

The company relies on external manufacturers and trial operators, creating execution and supply risk.

Scope
Clinical supply and trial timelines
Materiality
medium
medium

Commercialization and reimbursement risk

Even if approved, products may face pricing pressure and reimbursement barriers that limit uptake.

Scope
Future marketed products
Materiality
medium
Grant income recognition
Affects reported operating loss and comparability across periods
Clinical trial and R&D accrual estimates
Can move quarterly R&D expense materially
Foreign exchange translation
Creates volatility in other income/expense
Going-concern disclosure
Important for liquidity assessment and valuation

ADMA BIOLOGICS, INC.

ADMA · Biological Products, (No Diagnostic Substances)

DYADIC INTERNATIONAL INC

DYAI · Biological Products, (No Diagnostic Substances)

Edgewise Therapeutics, Inc.

EWTX · Pharmaceutical Preparations

Editas Medicine, Inc.

EDIT · Biological Products, (No Diagnostic Substances)

PDS Biotechnology Corp

PDSB · Pharmaceutical Preparations

IDEAYA Biosciences, Inc.

IDYA · Pharmaceutical Preparations

: 28.4.2026